ArticleTranslational cancer research2019
Role of PRMT5 in bladder cancer: a comprehensive study.
Article in Translational cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough previous studies have reported the abnormal expression of the protein arginine methyltransferase 5 (PRMT5) in a variety of cancers, the function and potential mechanism of PRMT5 in bladder cancer (BCa) remain unclear. Therefore, we attempt to illuminate the biological and clinicopathological significance of PRMT5 expression in BCa in this work.
methodsAnalysis of the database from The Cancer Genome Atlas (TCGA) and a real-time quantitative polymerase chain reaction (RT-qPCR) analysis were performed to assess the clinicopathological significance of PRMT5 in BCa. A PRMT5 knockdown model was constructed by the lentivirus-mediated shRNA infection of the SW780 cells to evaluate the biological function of PRMT5 in BCa cells using
resultsBased on results from data gathered from TCGA database and RT-qPCR, PRMT5 was found to be overexpressed in BCa tissues and cells. This result shows the potential value in the prognosis and treatment of BCa. PRMT5 expression was also negatively associated with overall survival (OS) (P=0.006, log-rank test =7.537) and recurrence-free survival (RFS) (P=0.0179, log-rank test =5.606) in TCGA data. Meanwhile,
conclusionsIn summary, the results suggest that PRMT5 could be used as a common molecular biomarker for the prognosis and treatment of BCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.